US Patent Issued to Qlaris Bio, Mayo Foundation for Medical Education and Research on Oct. 28 for "Controlled-delivery cromakalim prodrugs" (American, British Inventors)

ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,454,539, issued on Oct. 28, was assigned to Qlaris Bio Inc. (Dedham, Mass.) and Mayo Foundation for Medical Education and Research (Rochester, Minn.).

"Controlled-delivery cromakalim prodrugs" was invented by Thurein M. Htoo (Waban, Mass.), Barbara M. Wirostko (Park City, Utah), Michael P. Fautsch (Rochester, Minn.), Ian Garnett (Didcot, Great Britain) and Chiara Massarenti (Oxford, Great Britain).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides cromakalim phosphate prodrugs, compositions, and their use for the modulation of ATP-sensitive potassium (KATP) channels for therapeutic purposes."

The patent was filed on June 9, 20...